About 20 states have moved to ban copay accumulators.
An increasing number of patients are receiving copay assistance from drug manufacturers and others to help cover the cost of expensive medications. Until fairly recently, the funding from those programs, which can easily run into the thousands of dollars per year, did not count toward a patient’s deductible or out-of-pocket maximum. As a result, a fair number of patients paid very little if anything out of pocket for expensive drugs. With copay accumulators, pharmacy benefit managers (PBMs) count the copay amounts covered by the copay assistance programs toward a patient’s deductible and out-of-pocket maximum. When the copay assistance program runs out, patients may suddenly have to pay the full price of an expensive drug until they reach the deductible or out-of-pocket maximum of their health insurance policies.
Health insurers and PBMs say the accumulator programs counteract the copay assistance programs, which are helpful to individual patients but undercut formularies, lead to the prescription of expensive drugs and may eventually result in higher premiums. Patient groups say accumulator programs make important drugs more expensive and cause harm because people can’t afford their medications after the copay assistance support runs out and they have to pay full price till the deductible is met.
About 20 states have moved to ban copy accumulators. Patient groups have mounted legal challenges. The federal Help Ensure Lower Patient (HELP) Copay Act, introduced in the House and the Senate, would ban accumulators.
Should copay accumulators be banned?
We want to know what you’re thinking! Every Monday morning the editors of Managed Healthcare Executive are posing a question to our readers about a timely issue in U.S. healthcare. Answers will be published every Friday.
Unrealistic Portrayals of Cardiac Arrest in Contemporary Film | ACC 2025
March 31st 2025Cardiac arrests in contemporary film are largely inaccurate when it comes to survival rate and etiology, according to a poster presented today at the American College of Cardiology conference held March 29 to 31 in Chicago.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Winrevair Reduced Risk of Morbidity and Mortality by 76% in PAH | ACC 2025
March 31st 2025In the ZENITH trial, Winrevair was evaluated based on a composite endpoint of all-cause death, lung transplantation or disease-related hospitalization for patients with pulmonary arterial hypertension.
Read More
Clopidogrel Beat Aspirin in Preventing Heart Attacks After PCI | ACC 2025
March 31st 2025Clopidogrel monotherapy may be an alternative to aspirin for prevention of cardiac events in high-risk patients after percutaneous coronary intervention, according to a new study presented at ACC 2025.
Read More